Here's Why Grail Soared, Again, in November

Early cancer detection is highly beneficial to sufferers, and Grail's Galleri test offers a solution. The company is the leader in the race for FDA approval, but it could benefit from being part of a larger company.

The Motley Fool • Dec 2, 2025

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MENLO PARK, Calif. , Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

PRNewsWire • Dec 1, 2025

Deutsche Bank may have just set a holy-grail goal for the S&P 500

Deutsche Bank appears to have set a high mark when it comes to forecasts for the S&P 500 in 2026, with a target of 8,000.

Market Watch • Nov 24, 2025

Why GRAIL Stock Could Be Biotech's Next Big Breakout

Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best times in history to build wealth—especially if you think long-term and stay grounded in time-tested principles.

MarketBeat • Nov 19, 2025

GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference

MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m.

PRNewsWire • Nov 18, 2025

Why Grail Stock Zoomed Nearly 7% Higher on Monday

The cancer diagnostics specialist received two price target increases from separate analysts. One more than doubled his on the company.

The Motley Fool • Nov 18, 2025

Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold

Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detection, yet questions remain about detection rates, pricing, and broad adoption, in my view. GRAL's stock has surged 185% since my last Hold call, despite lack of FDA approval and ongoing uncertainty around reimbursement, market size, and future profitability.

Seeking Alpha • Nov 13, 2025

GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript

GRAIL, Inc. ( GRAL ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - Chief Scientific Officer & President International Aaron Freidin - Chief Financial Officer Andrew Partridge - Chief Commercial Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Douglas Schenkel - Wolfe Research, LLC Bradley Bowers - Mizuho Securities USA LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded.

Seeking Alpha • Nov 12, 2025

GRAIL Reports Third Quarter 2025 Financial Results

Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position of More Than $850 Million Includes Recently Completed Private Placement MENLO PARK, Calif. , Nov. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025.

PRNewsWire • Nov 12, 2025

Here's Why Grail Stock Exploded Higher by 55% in October

Investors and a powerhouse Asian conglomerate are supporting Grail's development. The company's Galleri test offers the potential to screen for more than 50 different cancers in a single test.

The Motley Fool • Nov 6, 2025